Barclays’s Haemonetics HAE Stock Holding History

Barclays’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$4.48M	–	7229
2018 Q2	$4.48M	Buy	+50,000	New	+$4.22M	﹤0.01%	1812

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's HAE Position: Q2 2026 in Review

Barclays increased its Haemonetics (HAE) stake by 29% in Q2 2026, buying an estimated $517K and bringing the position to 36,199 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

Barclays first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.4M in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Barclays held 36,199 shares of Haemonetics worth $2.71M as of Q2 2026.
Barclays bought 8,046 Haemonetics shares in Q2 2026, an estimated $517K.
Haemonetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2188 holding.
Barclays first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
Barclays's Haemonetics position peaked at $16.4M in Q2 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.